Propranolol reduces viability and induces apoptosis in hemangioblastoma cells from von Hippel-Lindau patients
© Albiñana et al. 2015
Received: 22 May 2015
Accepted: 16 September 2015
Published: 22 September 2015
Von Hippel-Lindau (VHL) disease is a rare oncological disease with an incidence of 1:36,000, and is characterized by the growth of different types of tumors: hemangioblastomas in the central nervous system (CNS) and retina, renal carcinoma, pheochromocytomas, pancreatic serous cystadenoma, and endolymphatic sac tumors. These tumors do not express VHL protein (pVHL). pVHL ubiquitinates hypoxia inducible factor (HIF) protein for degradation by the proteasome; in the absence of VHL, HIF translocates to the nucleus to activate the expression of its target genes. Targeting VHL-derived tumors with drugs that have reduced side effects is urgent to avoid repeat CNS surgeries. Recent reports have shown that propranolol, a β-blocker used for the treatment of hypertension and other cardiac and neurological diseases, is the best option for infantile hemangioma (IH). Propranolol could be an efficient treatment to control hemangioblastoma growth in VHL disease because of its antiangiogenic effects demonstrated in IH and the hypothetical impact on HIF levels.
HeLa 9X (HRE) hypoxia responsive element cell line and primary hemangioblastoma-derived cells were subjected to propranolol treatment and cell viability and apoptosis were evaluated. HIF1-α and Hif-2α expression after propranolol treatment was analyzed by western blotting. Quantitative PCR was performed to study the mRNA expression of HIF target genes. Vascular endothelial growth factor (VEGF) was measured in culture supernatants by immunoassay.
Propranolol downregulated HIF-dependent transcription in HeLa 9XHRE cells. Under hypoxic conditions, propranolol decreased the expression of HIF target genes in hemangioblastoma cells, which stopped proliferating and died following long-term treatment. These results suggests that propranolol treatment promoted reduced HIF protein expression and corresponding downregulation of HIF target genes, and inhibited cell proliferation in parallel with induction of cell death by apoptosis.
Our results suggest that propranolol could reduce the growth of HIF-dependent tumors and may thus be a promising treatment to delay surgery in VHL patients.
Keywordsvon Hippel-Lindau disease (VHL) pVHL Hypoxia inducible factor hemangioblastoma CNS tumors Propranolol
Von Hippel-Lindau (VHL) disease is a rare type of phacomatosis with an incidence of 1 per 36,000 individuals in the general population [1, 2]. The clinical manifestations include multiple benign and malignant tumors that appear throughout the lifespan of the patient. The most frequent tumors are hemangioblastomas (HB) of the central nervous system (CNS) and retina, and renal cell carcinoma [3–6]. In addition, pheochromocytomas, pancreatic serous cystadenoma, endolymphatic sac tumors and papillary cystadenomas are associated with the disease.
VHL disease is an inherited entity, with autosomal dominant transmission. Patients are heterozygous for mutations in VHL, a tumor suppressor gene located on the short arm of chromosome 3 (3p25–p26). Tumors develop in patients who have a mutated copy of VHL at birth following loss of the wild-type allele (loss of heterozygosity) . Thus, the tumors of these patients either do not express VHL protein (pVHL) or the mutated form is not functional. pVHL binds to and ubiquitinates HIF-1α and HIF-2α to target them to the proteasome for degradation. Therefore, in the absence of functional pVHL, HIF accumulates within the cytoplasm and translocates to the nucleus to trigger the hypoxia program by targeting hypoxia responsive genes . HIF-1α and HIF-2α are involved in cell proliferation, angiogenesis, extracellular matrix degradation, vascular tone, and erythropoiesis, among other processes. All HIF target genes are normally silenced in normoxia. pVHL cannot bind HIF in hypoxic conditions, since prolylhydroxylases cannot hydroxylate specific proline residues of HIF. In these circumstances, HIF accumulates and translocates to the nucleus. Therefore, cells from VHL tumors have a constitutively active HIF program due to the absence of functional pVHL.
Thus far, the therapeutic options for VHL patients are derived from surgery [9, 10]. The systemic therapy used for metastatic cancers has shown limited response in VHL pancreatic and renal tumors, while CNS tumors do not respond at all. Therefore, the lack of therapies for diffuse or recurrent disease means there is an urgent requirement for effective drugs with reduced side effects for VHL patients, especially those that halt the progression of tumors and subsequently delay surgical treatment. Some previous studies have shown that propranolol, a β-blocker used for the treatment of arrhythmia, hypertension, migraines, and other cardiac and neurological diseases, is also the best option for the treatment of infantile hemangioma (IH) [11–15]. IH is the most frequent vascular benign tumor in newborns. In the last few years, propranolol has become the choice treatment for IH over surgery, with a long list of publications supporting its success. In relation to this, our group has demonstrated that endothelial cells treated with propranolol showed decreased expression of the pro-angiogenic proteins endoglin and ALK1, which are HIF-1α targets . Although the precise mechanism of action of propranolol is unclear, upon blocking β-adrenergic receptors, propranolol leads to vasoconstriction (reducing the blood flow), apoptosis induction, and inhibition of angiogenic HIF target genes such as vascular endothelial growth factor (VEGF), fibroblast growth factor (FGF) or metalloproteases (MMPs).
Therefore, these results led us to consider the hypothesis that propranolol could be an efficient treatment for hemangioblastomas through inhibition of HIF in highly vascularized tumors in which HIF is constitutively expressed.
HeLa 9XHRE cells were stably transfected with a HRE-luc reporter carrying nine copies in tandem of the hypoxia responsive element (HRE) followed by luciferase gene, and were cultured in DMEM (Dulbecco’s Modified Eagle Medium, Gibco, Grand Island, NY, USA) supplemented with 10 % fetal bovine serum (FBS; Gibco), 2 mM L-glutamine and 100 U/ml penicillin/streptomycin (Gibco). To induce hypoxic conditions, HeLa cells were cultured either with 100 μM desferrioxamine (DFO) (chemical hypoxia) or incubated in a hypoxic chamber (Billups-Rothemberg, Inc, Del Mar, CA) in 1 % oxygen, 5 % CO2 and 94 % N2, for 24 h.
Primary cultures of CNS hemangioblastoma were obtained according to the previously novel protocol designed by Serrano-Heras and scientific collaborators from General University Hospital of Albacete, Spain (Manuscript in preparation). Between March 2013 and march 2014 clinical samples from 4 patients (3 men and 1 woman, mean range 31.5 ± 15.6 years, and range: 13–45) diagnosed of Von Hippel-Lindau disease were taken collected from the Neurosurgery department at “Fundación Jiménez Díaz”, Universitary Hospital, Spain. Prior informed consent written forms were obtained from all patients. All procedures had been previously approved by the Ethics Committee in accordance with general accepted guidelines for human samples. The collected fresh tissue from the excess of resected hemangioblastoma was placed in sterilized tubes containing ice-cold Earle’s Balanced Salt Solution (EBSS, Gibco). Tumor samples were washed several times with PBS, and cut into 1 mm3 pieces. Tissue pieces were transferred with sterile tweezers to clean cell culture dishes (Sarstedt, Germany) and subjected to enzymatic digestion with equal amount of collagenase I and dispase II to a final concentration of 1 mg/m in EBSS, for 45 min at 37 °C. After that, the pieces were completely disaggregated by gently pipetting and digested for 15 min with trypsin at 37 °C. Then, minced samples were centrifuged, cell pellets were suspended in growth medium (RPMI 1640 (Gibco) supplemented with 20 % fetal bovine serum, 1 % Pen/Strep and 4 mM of glutamine), and incubated at 37 °C. Medium was replaced every 72 h until the cultures were confluent.
Furthermore, Flow Cytometry was performed for cell characterization. The analysis showed that cultures were composed of stromal cells (30–50 % CD99 + cells), endothelial cells (15–25 % CD34+ cells), and pericytes (30–40 % NG2+ cells). The experiments were performed in all types of cells composing the hemangioblastoma. A total of four hemangioblastomas from different patients were assayed in culture, with the following localization: HB2, spinal bulb; HB3, temporal lobe; HB7, spinal cord; HB11, temporal lobe.
Total cellular RNA was extracted from hemangioblastoma cells using a Nucleo Spin RNA kit (Macherey-Nagel, Düren, Germany). One microgram of total RNA was reverse-transcribed in a final volume of 20 μl with the First Strand cDNA Synthesis Kit (Roche, Mannheim, Germany) using random primers. SYBR Green PCR system (BioRad, Hercules, CA, USA) was used to carry out real-time PCR with an iQ5 system. The sequences of the oligonucleotides used corresponded to HIF-1α and -2α target genes, as follows: VEGF forward: 5’-ATCTGAGCAGGGCGACAGC-3’ and reverse 5’-ACTCCCTGTGGTGCAGTCA-3’; EPO forward 5’-TGTTTTCGCACCTACCATCA-3’ and reverse 5’-AAGTCACAGCTTGCCACCT-3’; and SOX2 forward 5’-GGGGGAATGGACCTTGTATAG-3’ and reverse 5’-CGCTCCACCAACTAAGAACG-3’. As an internal control, mRNA levels of 18S were measured using the following primers: forward 5’-CTCAACACGGGAAACCTCAC-3’ and reverse 5’-CGCTCCACCAACTAAGAACG-3’. Amplicons were detected using an iQ5 system (BioRad). The samples were used in triplicate and the experiment was repeated twice.
Western blot analysis
Cells were lysed on ice for 30 min in TNE buffer (Tris 50 mM NaCl 150 mM-EDTA 1 mM 0.5 % Triton X100) supplemented with protease inhibitors (Complete Roche Diagnostics) and lactacystin as a specific proteasome inhibitor to preserve HIF. Lysates were centrifuged at 14,000 × g for 5 min. Similar amounts of proteins from aliquots of cleared cell lysates were boiled in SDS sample buffer and analyzed by 10 % SDS-PAGE under non-reducing conditions. Proteins from gels were electrotransferred to nitrocellulose membranes followed by immunodetection with anti-HIF1α (BD, Bedford, MA, USA), anti-HIF-2α (NOVUS, Oxon, UK) and anti-γ-tubulin (Sigma, St.Louis, MO, USA) antibodies at the dilution recommended by the manufacturer. Secondary antibodies were horseradish peroxidase conjugates from Dako (Glostrup, Denmark). Membranes were developed by chemiluminescence (SuperSignal West Pico Chemiluminescent Substrate, Thermo Scientific, Rockford, IL, USA).
Luminescent cell viability assay
The viability of hemangioblastoma and HeLa 9X HRE cells was measured with a CellTiter-Glo Luminescent Cell Viability Assay (Promega, Madison, WI, USA). This is a homogeneous method to determine the number of viable cells in culture based on quantitation of the ATP present, which signals the presence of metabolically active cells. A total of 10,000 cells were plated in 96-well plates and cultured for 24 h and 48 h with propranolol (50 μM and 100 μM) in 100 μl of medium. After treatment, plates were equilibrated to room temperature for 30 min before the addition of 100 μl of Cell Titer-Glo reagent (Lysis buffer, Ultra-Glo Recombinant Luciferase, Luciferine and Mg2+). Cell lysis was induced in an orbital shaker for 2 min, and then plates were incubated at room temperature for 10 min to stabilize the luminescent signal. Luminescence was measured using a Glomax Multidetection System (Promega).
Caspase activation assay
The Caspase-Glo 3/7 Assay (Promega) is a luminescent assay that measures caspase-3 and caspase-7 activity using a luminogenic caspase-3/7 substrate that contains the tetrapeptide sequence DEVD in a reagent optimized for caspase activity, luciferase activity and cell lysis. Luminescence is proportional to the amount of caspase activity present. A total of 10,000 hemangioblastoma cells were plated in 96-well plates and cultured for 24 h and 48 h with propranolol (50 μM and 100 μM) in 100 μl of medium. After treatment, plates were equilibrated to room temperature for 30 min before the addition of 100 μl of Caspase Glo 3/7 Reagent (lysis buffer, Ultra-Glo Recombinant Luciferase, DEVD-aminoluciferine and Mg2+). Cell lysis was induced by shaking for 30 s (300 rpm), and then plates were incubated at room temperature for 2 h. Luminescence was measured using a Glomax Multidetection System (Promega).
VEGF determination in plasma
A Quantikine Human VEGF ELISA kit from R&D Systems (Abingdon, UK) was used to quantitatively determine human VEGF-A concentration in supernatants of hemangioblastoma culture cells treated with propranolol at different doses.
Data represent mean ± SD. Differences in mean values were analyzed using the Student’s t-test. P-values of <0.05 were considered to be statistically significant; statistically significant values are marked with asterisks (*P < 0.05; **P < 0.01; ***P < 0.005).
Propranolol downregulates HIF-dependent transcription in 9XHRE HeLa cells
Propranolol decreases the expression of HIF target genes in hemangioblastoma cells
VEGF, one of the main targets of HIF-1α, and a potent mediator of both angiogenesis and vasculogenesis, was also measured in the supernatants of two different hemangioblastoma samples cultured with and without propranolol. As observed in Fig. 2b, the levels of VEGF were decreased by treatment with 50 μM propranolol, in agreement with the mRNA results (Fig. 2a).
Propranolol affects the viability of tumor cells and induces cell death by apoptosis
Altogether, we can conclude that propranolol decreases the viability of tumor cells (HeLa and VHL-derived hemangioblastoma cells) by stopping proliferation and inducing cell death by apoptosis. This result would be compatible with the regression observed in IH, and it would suggest that propranolol could delay the proliferation of hemangioblastomas in VHL patients.
It has been suggested that propranolol may act through different ways, including vasoconstriction, as an anti-angiogenic inhibiting VEGF production, and as a pro-apoptotic drug leading to cell apoptosis [11, 20, 29, 30]. However, its potential therapeutic benefits in different vascular anomalies remain to be explored.
Based on previous results of propranolol efficiency for IH treatment [12–15], and our own results showing that propranolol acts as antiangiogenic in endothelial cells by decreasing transcription levels of proangiogenic factors such as endoglin and ALK1 , we hypothesized that propranolol could act by decreasing HIF levels and therefore downregulating the HIF target program. As a putative side effect of propranolol treatment, concerns about long-term neurodevelopmental or cognitive effects of propranolol have recently arisen after a study by Langley and Pope . These authors argue that propranolol can cross the blood–brain barrier and can cause sleep and memory disturbances, as demonstrated by decreased specific memory functions in adults. This work was commented upon by Tozzi  in a letter to the Editor, and Léauté-Labrèze et al. responded  in the same issue of the journal. The reply is supported, first of all, by the lack of adverse events in children treated with propranolol. In fact, the rates of neurodevelopmental defects or delay observed among 272 propranolol-treated children from 2008 to 2013 seem to be within the range observed in the normal population. On the other hand, the article by Langley and Pope is essentially theoretical and not evidence-driven, and includes data from small studies in healthy adults.
Interestingly enough, all the HIF target genes, including among others, VEGF, MMPs, EPO or FGF, are absolutely necessary for the survival and progression of tumors in general, and for hemangioblastomas in particular. Hemangioblastomas are complex tumors consisting of different cellular types, with stromal (undifferentiated mesenchymal cells) and endothelial cells as the main components. Thus being so, propranolol might be able to stop vascular dependent growth of hemangioblastomas [2, 34].
In the present work, we have shown that propranolol downregulates HIF-1 targets. In fact, propranolol inhibited HIF-dependent transcription in a 9xHRE HeLa reporter cell line (Fig. 1) and the crucial gene targets for hemangioblastoma survival, such as VEGF, EPO and SOX2 (Fig. 2). EPO has been reported to be active in hemangioblastoma tumorlets of VHL patient [35–37], and according to Fig. 2a its expression was reduced by almost half in the presence of propranolol. On the other hand, VEGF was shown to be downregulated at the transcriptional level (Fig. 2a), but also as protein secreted into the culture supernatants of different hemangioblastomas cultivated in vitro (Fig. 2b). Moreover, the impaired angiogenesis of hemangioblastomas in matrigel is shown in Fig. 6, where the tubular network of untreated cells remained with unclosed cells at an intermediate dose of propranolol, and its formation was prevented at the highest propranolol dose. This is in agreement with the results obtained by Albiñana et al. (2012) where propranolol precluded the tube formation of treating EOMA and human endothelial cells at the highest dose.
Hemangioblastoma tissue is composed of neoplastic stromal cells and abundant reactive vascular cells [19, 24, 38]. VHL-deficient tumor cells have hemangioblastic differentiation capacity [39, 40]. Stromal cells are undifferentiated cells of mesenchymal nature, where SOX-2 master stemness marker is expressed as a HIF-2α target. Thus, we explored the expression of SOX-2 in hemangioblastoma before and after propranolol treatment, and SOX-2 levels were also significantly decreased by propranolol (Fig. 2).
We established that propranolol decreased HIF-dependent transcription in 9XHRE HeLa cells under hypoxia and in hemangioblastoma cells constitutively expressing HIF, as shown in Fig. 7a, the amounts of HIF1α and HIF2α protein under hypoxic conditions in HeLa cells were decreased by propranolol treatment. This fact was also tested in hemangioblastoma cells that were functionally hypoxic, as shown by the expression of HIF1α and HIF2α under normal culture conditions. Western blotting demonstrated that both HIF-1α and 2α were decreased by propranolol treatment at the protein level (Fig. B).
Next, we explored whether propranolol could interfere with proliferation and survival of hemangioblastoma cells. As HIF triggers the hypoxia gene program to maintain cell survival, the previous results suggested that propranolol also affected cell viability. In fact, Fig. 3 demonstrates that propranolol reduced the viability of HeLa cells under hypoxic conditions. The cause of death was determined to be apoptosis, as measured by the activity of caspases 3/7, which was increased by three-fold over untreated cells at the highest dose of propranolol. Interestingly, the same holds true when the viability and apoptosis of hemangioblastoma cells from different VHL patients were evaluated after propranolol treatment. Figure 4 shows that hemangioblastoma cell viability may drop by up to 50 % after 48 h, and that apoptosis is increased between 2.5- and 5-fold following 48 h of 100 μM propranolol treatment.
Given these results, our assumption was that, if propranolol treatment was sustained in time, cells would disappear as is shown in Fig. 5 in hemangioblastoma cells. Notably, after 96 h at 100 μM propranolol treatment, very few cells remained attached to the wells, and those that remained alive had an extremely thin and elongated shape, showing the appearance of apoptotic cells.
In conclusion, our results suggest that propranolol reduces the growth of HIF-dependent tumors, and may be a promising therapeutic drug to delay surgery in VHL patients.
Activin receptor like kinase 1
Central nervous system
Dulbecco’s modified Eagle medium
Mouse hemangioendothelioma edothelial cells
Fetal bovine serum
Fibroblast growth factor
Hypoxia inducible factor
Hypoxia responsive element
Von Hippel Lindau protein
Roswell Park Memorial Institute
Reverse transcription polymerase chain reaction
Sodium dodecyl sulfate-polyacrylamide gel electrophoresis
- SOX-2 or SRY-box 2:
Sex-determining region Y-box
Vascular endothelial growth factor
This work was supported by grants from Ministerio de Economia y Competitividad SAF2011-23475 and from Alianza VHL Spain& Fundación Iberdrola to LMB. Virginia Albiñana was supported by Alianza VHL Spain, Fundación Iberdrola and Fundación Divina Pastora. We are grateful to the patients who participated in our research, and we thank the physicians Pablo de Andrés and Delia Viñas (Fundación Jiménez Díaz, Madrid, Spain) who participated in the collection of patient samples and data and Dr Blanca Carrión as scientific collaborator in obtaining primary cultures of CNS hemangioblastoma.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- Maher ER, Neumann HP, Richard S. Von Hippel-Lindau disease: a clinical and scientific review. Eur J Hum Genet. 2011;19:617–23.PubMed CentralView ArticlePubMedGoogle Scholar
- Richard S, Gardie B, Couvé S, Gad S. Von Hippel-Lindau: how a rare disease illuminates cancer biology. Semin Cancer Biol. 2013;23(1):26–37.View ArticlePubMedGoogle Scholar
- Kaelin Jr WG. Molecular basis of the VHL hereditary cancer syndrome. Nat Rev Cancer. 2002;2(9):673–82.View ArticlePubMedGoogle Scholar
- Kaelin Jr WG. The von Hippel-Lindau tumor suppressor protein: O2 sensing and cancer. Nat Rev Cancer. 2008;8(11):865–73.View ArticlePubMedGoogle Scholar
- Bausch B, Jilg C, Gläsker S, Vortmeyer A, Lützen N, Anton A, et al. Renal cancer in von Hippel-Lindau disease and related syndromes. Nat Rev Nephrol. 2013;9(9):529–38.View ArticlePubMedGoogle Scholar
- Vortmeyer AO, Falke EA, Gläsker S, Li J, Oldfield EH. Nervous system involvement in von Hippel-Lindau disease: pathology and mechanisms. Acta Neuropathol. 2013;125(3):333–50.View ArticlePubMedGoogle Scholar
- Gläsker S, Bender BU, Apel TW, van Velthoven V, Mulligan LM, Zentner J, et al. Reconsideration of biallelic inactivation of the VHL tumor suppressor gene in hemangioblastomas of the central nervous system. J Neurol Neurosurg Psychiatry. 2001;70(5):644–8.PubMed CentralView ArticlePubMedGoogle Scholar
- Bader HL, Hsu T. Systemic VHL gene functions and the VHL disease. FEBS Lett. 2012;586(11):1562–9.PubMed CentralView ArticlePubMedGoogle Scholar
- Haddad NM, Cavallerano JD, Silva PS. Von hippel-lindau disease: a genetic and clinical review. Semin Ophthalmol. 2013;28(5–6):377–8.View ArticlePubMedGoogle Scholar
- Kassardjian CD, Macdonald RL, Munoz DG. Hemangioblastomas in the elderly: epidemiology and clinical characteristics. J Clin Neurosci. 2014;21(7):1205–8.View ArticlePubMedGoogle Scholar
- Sanchez-Carpintero I, Ruiz-Rodrig R, Lopez-Gutierrez JC. propranolol in the treatment of infantile hemangioma: clinical effectiveness, risks, and recommendations. Actas Dermosifiliogr. 2011;102:766–79.View ArticlePubMedGoogle Scholar
- Léauté-Labrèze C, Hoeger P, Mazereeuw-Hautier J, Guibaud L, Baselga E, Posiunas G, et al. A randomized, controlled trial of oral propranolol in infantile hemangioma. N Engl J Med. 2015;372(8):735–46.View ArticlePubMedGoogle Scholar
- Storch CH, Hoeger PH. propranolol for infantile haemangiomas: insights into the molecular mechanisms of action. Br J Dermatol. 2010;163:269–74.View ArticlePubMedGoogle Scholar
- Lamy S, Lachambre MP, Lord-Dufour S, Béliveau R. propranolol suppresses angiogenesis in vitro: inhibition of proliferation, migration, and differentiation of endothelial cells. Vasc Pharmacol. 2010;53:200–8.View ArticleGoogle Scholar
- Leaute-Labreze C, de la Dumas Roque E, Hubiche T, Boralevi F, Thambo JB, Taïeb A. propranolol for severe hemangiomas of infancy. N Engl J Med. 2008;358:2649–51.View ArticlePubMedGoogle Scholar
- Albiñana V, Recio-Poveda L, Zarrabeitia R, Bernabéu C, Botella LM. propranolol as antiangiogenic candidate for the therapy of hereditary haemorrhagic telangiectasia. Thromb Haemost. 2012;108(1):41–53.View ArticlePubMedGoogle Scholar
- Ponnaluri VK, Vavilala DT, Prakash S, Mukherji M. Hypoxia mediated expression of stem cell markers in VHL-associated hemangioblastomas. Biochem Biophys Res Commun. 2013;438(1):71–7.View ArticlePubMedGoogle Scholar
- Flamme I, Krieg M, Plate KH. Up-regulation of vascular endothelial growth factor in stromal cells of hemangioblastomas is correlated with up-regulation of the transcription factor HRF/HIF-2alpha. Am J Pathol. 1998;153(1):25–9.PubMed CentralView ArticlePubMedGoogle Scholar
- Gläsker S, Smith J, Raffeld M, Li J, Oldfield EH, Vortmeyer AO. VHL-deficient vasculogenesis in hemangioblastoma. Exp Mol Pathol. 2014;96(2):162–7.View ArticlePubMedGoogle Scholar
- Sommers Smith SK, Smith DM. Beta blockade induces apoptosis in cultured capillary endothelial cells. In Vitro Cell Dev Biol Anim. 2002;38:298–304.View ArticlePubMedGoogle Scholar
- Maher ER, Yates JR, Harries R, Benjamin C, Harris R, Moore AT, et al. Clinical features and natural history of von Hippel-Lindau disease. Q J Med. 1990;77(283):1151–63.View ArticlePubMedGoogle Scholar
- Lonser RR, Glenn GM, Walther M, Chew EY, Libutti SK, Linehan WM, et al. Von Hippel-Lindau disease. Lancet. 2003;361(9374):2059–67.View ArticlePubMedGoogle Scholar
- Knudson Jr AG. Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci U S A. 1971;68(4):820–3.PubMed CentralView ArticlePubMedGoogle Scholar
- Vortmeyer AO, Gnarra JR, Emmert-Buck MR, Katz D, Linehan WM, Oldfield EH, et al. Von Hippel-Lindau gene deletion detected in the stromal cell component of a cerebellar hemangioblastoma associated with von Hippel-Lindau disease. Hum Pathol. 1997;28(5):540–3.View ArticlePubMedGoogle Scholar
- Semenza GL. Regulation of metabolism by hypoxia-inducible factor 1. Cold Spring Harb Symp Quant Biol. 2011;76:347–53.View ArticlePubMedGoogle Scholar
- Ke Q, Costa M. Hypoxia-inducible factor-1 (HIF-1). Mol Pharmacol. 2006;70(5):1469–80.View ArticlePubMedGoogle Scholar
- Manalo DJ, Rowan A, Lavoie T, Natarajan L, Kelly BD, Ye SQ, et al. Transcriptional regulation of vascular endothelial cell responses to hypoxia by HIF-1. Blood. 2005;105(2):659–69.View ArticlePubMedGoogle Scholar
- Périgny M, Hammel P, Corcos O, Larochelle O, Giraud S, Richard S, et al. Pancreatic endocrine microadenomatosis in patients with von Hippel-Lindau disease: characterization by VHL/HIF pathway proteins expression. Am J Surg Pathol. 2009;33(5):739–48.View ArticlePubMedGoogle Scholar
- England RW, Hardy KL, Kitajewski AM, Wong A, Kitajewski JK, Shawber CJ, et al. propranolol promotes accelerated and dysregulated adipogenesis in hemangioma stem cells. Ann Plast Surg. 2014;73 Suppl 1:S119–24.PubMed CentralView ArticlePubMedGoogle Scholar
- Wong A, Hardy KL, Kitajewski AM, Shawber CJ, Kitajewski JK, Wu JK. Propranolol accelerates adipogenesis in hemangioma stem cells and causes apoptosis of hemangioma endothelial cells. Plast Reconstr Surg. 2012;130(5):1012–21.PubMed CentralView ArticlePubMedGoogle Scholar
- Langley A, Pope E. Propranolol and central nervous system function: potential implications for paediatric patients with infantile haemangiomas. Br J Dermatol. 2015;172(1):13–23.View ArticlePubMedGoogle Scholar
- Tozzi A. Oral Propranolol for Infantile Hemangioma. N Engl J Med. 2015;373(3):284.View ArticlePubMedGoogle Scholar
- Léauté-Labrèze C, Voisard JJ, Moore N. Oral Propranolol for Infantile Hemangioma. N Engl J Med. 2015;373(3):284–5.View ArticlePubMedGoogle Scholar
- Wizigmann-Voos S, Plate KH. Pathology, genetics and cell biology of hemangioblastomas. Histol Histopathol. 1996;11(4):1049–61.PubMedGoogle Scholar
- Ang SO, Chen H, Gordeuk VR, Sergueeva AI, Polyakova LA, Miasnikova GY, et al. Endemic polycythemia in Russia: mutation in the VHL gene. Blood Cells Mol Dis. 2002;28(1):57–62.View ArticlePubMedGoogle Scholar
- Liu E, Percy MJ, Amos CI, Guan Y, Shete S, Stockton DW, et al. The worldwide distribution of the VHL 598C > T mutation indicates a single founding event. Blood. 2004;103(5):1937–40.View ArticlePubMedGoogle Scholar
- Franke K, Gassmann M, Wielockx B. Erythrocytosis: the HIF pathway in control. Blood. 2013;122(7):1122–8.View ArticlePubMedGoogle Scholar
- Lee JY, Dong SM, Park WS, Yoo NJ, Kim CS, Jang JJ, et al. Loss of heterozygosity and somatic mutations of the VHL tumor suppressor gene in sporadic cerebellar hemangioblastomas. Cancer Res. 1998;58(3):504–8.PubMedGoogle Scholar
- Shively SB, Beltaifa S, Gehrs B, Duong H, Smith J, Edwards NA, et al. Protracted haemangioblastic proliferation and differentiation in von Hippel-Lindau disease. J Pathol. 2008;216(4):514–20.View ArticlePubMedGoogle Scholar
- Vortmeyer AO, Tran MG, Zeng W, Gläsker S, Riley C, Tsokos M, et al. Evolution of VHL tumourigenesis in nerve root tissue. J Pathol. 2006;210(3):374–82.View ArticlePubMedGoogle Scholar